Articles tagged with Sickle Cell Anemia
Researchers use protein-engineering techniques to force chromatin fiber into looped structures that activate genes regulating fetal hemoglobin, which is not affected by the inherited mutation causing sickle cell disease. The approach may give rise to a new therapy for the debilitating blood disorder.
A new study found that two beneficial variants of a gene controlling red blood cell development have spread from Africa to nearly all human populations globally. These variants promote fetal haemoglobin production in adulthood, leading to milder symptoms of inherited blood disorders like sickle cell anaemia and thalassaemia.
Drs. DeBaun and Hebbel will present their lecture on sickle cell disease, highlighting improved understanding but continued challenges. Their research focuses on cerebrovascular injury and asthma, with implications for treatment and care.
A drug candidate developed to treat sickle cell disease has been acquired by Baxter International, advancing its clinical development activities. Aes-103 significantly reduces patients' pain in Phase II clinical trials, offering a potential breakthrough treatment.
A recent study shows that half of patients with severe sickle cell disease have safely stopped immunosuppressant medication after a modified blood stem-cell transplant. The trial reversed the condition in nearly all patients and allowed them to achieve stable mixed donor chimerism.
A new bone marrow transplantation method has shown promising results in treating adults with severe sickle cell disease, achieving long-term stable donor engraftment and improved hemoglobin levels. The study's findings suggest that this procedure can be applied to older adults with fewer toxic effects.
Researchers identified differences in pneumococcal genome that explain why vaccines don't protect children with sickle cell disease from infections. The study's findings will aid efforts to improve vaccine effectiveness and inform research into new protection methods.
A new assessment tool for young adults with sickle cell disease has been developed to gauge their readiness for adult care. The tool, which was found to be effective in pinpointing areas of need, includes a comprehensive guidebook addressing personal concerns and knowledge gaps.
Researchers found that low oxygen and nitric oxide levels increase red blood cell adhesion to blood vessel walls, leading to debilitating pain crises in sickle cell patients. Restoring normal nitric oxide levels can substantially reduce this adhesion, making it a potentially new therapeutic target.
The new guidelines recommend regular screening for pulmonary hypertension in SCD adults, and intensifying SCD therapy for those with PH. Patients with symptomatic PH should be treated, while management is guided by hemodynamic numbers obtained through catheterization.
The American Thoracic Society has developed guidelines to identify and manage patients with sickle cell disease who are at increased risk of mortality from pulmonary hypertension. Guidelines recommend treatment with hydroxyurea, chronic transfusion therapy, or indefinite anticoagulant therapy in patients with confirmed pulmonary hypert...
Studies found that African-American hemodialysis patients with sickle cell trait received about 13% more anemia medications than those without the trait to achieve the same level of hemoglobin. The presence of sickle cell trait was also more common among dialysis patients, affecting approximately 10% of study participants.
Researchers at Case Western Reserve University are working on a new device that can predict when patients with sickle cell disease will suffer an acute crisis and monitor the effectiveness of treatments. The device measures the physical properties of red blood cells, which become sticky and block blood flow during a crisis.
Researchers present new pain management treatment for SCD patients using selectin inhibitors, while also exploring targeted gene therapy strategies to produce healthy hemoglobin. These advances aim to improve the long-term outlook and quality of life for hundreds of thousands of patients worldwide.
Researchers used light-scattering techniques to study the detailed thermodynamics of hemoglobin fibers in sickle cell disease. They found that hemoglobin molecules associate more easily in high temperatures and concentrated solutions, leading to stronger bonds between fibers.
Researchers found that hemin injection caused labored breathing, lung injury and rapid death in sickle mice, but not in control mice. Hemopexin was an effective treatment against hemin-induced lung injury.
Researchers at Emory University discovered that hemin injection causes labored breathing and rapid death in sickle mice, but not in control mice. Hemopexin treatment was effective in preventing hemin-induced lung injury. These findings suggest targeting hemin and TLR4 signaling may be a valuable approach for treating acute chest syndrome.
Researchers are working on a new treatment approach to block kidney and lung damage, as well as pain associated with sickle cell disease. The study aims to explore the therapeutic possibilities of endothelin antagonists, which selectively block the endothelin A receptor, and bosentan, which blocks both A and B receptors.
A recent clinical study found that arginine therapy significantly reduces the need for pain medication and lowers pain scores in children with sickle cell disease. The treatment also shows promise as a potential cure for acute pain episodes, with no safety concerns reported.
New research shows hydroxyurea treatment can lower medical costs for children with sickle cell disease by preventing complications and reducing hospitalizations. The study found that children treated with hydroxyurea incurred $3,000 less in medical costs per year compared to those who received standard therapy plus placebo.
A new study led by St. Jude Children's Research Hospital found that a proven drug effective for adults and children with sickle cell anemia reduced hospitalizations and medical costs for young children by 21% annually.
Two Tufts University biomedical graduate students, Seblewongel Asrat and Jennifer Nwankwo, have been awarded HHMI International Student Research Fellowships to study Legionnaires' disease and sickle cell disease. The fellowships provide $43,000 in funding for the first year, with renewal opportunities for two additional years.
Sickle cell anemia is projected to increase by 33% from 2010 to 2050, primarily affecting newborns in sub-Saharan Africa. Implementing basic health interventions could significantly reduce death rates among children under 5 with the condition.
Researchers at UCLA's Eli and Edythe Broad Center have successfully established a foundation for using hematopoietic stem cells to treat sickle cell disease. The breakthrough technique uses anti-sickling genes to create healthy red blood cells that do not sickle, offering a revolutionary alternative to current treatments.
Researchers have successfully used a genetic vector to efficiently transduce bone marrow cells from SCD patients, suggesting a potential treatment method. The study's findings support the use of autologous HSC transplant with genetically modified patient cells to treat sickle cell disease.
Researchers from Brown University have developed computer models that show how different types of red blood cells interact to cause sickle cell crisis. The findings suggest that softer, deformable red blood cells known as SS2 cells start the process by sticking to capillary walls, leading to blockages.
Researchers from La Jolla Institute, Dana-Farber and BloodCenter of Wisconsin are launching Phase II clinical trials to investigate a potential new therapy for reducing sickle cell anemia symptoms. The trial is testing Lexiscan, an existing drug with anti-inflammatory effects.
Scientists need to find better ways to prevent sickling in red blood cells, which impairs oxygen delivery and damages blood vessel walls and organs. Anti-sickling therapies are crucial to reducing damage and improving patient outcomes.
Researchers found diverse consequences of opioid use in patients with sickle cell disease, including biological, psychological, social, and spiritual effects. The study used a grounded theory approach to gather data from 21 African-American adults with SCD, revealing divergent effects on relationships, productivity, mood, and outlook.
Researchers discover that tranylcypromine can reverse the effects of sickle cell disease in mice and human red blood cells. This breakthrough could lead to new treatments for the life-threatening condition, which causes misshapen red blood cells to cause vascular damage and premature death.
Researchers at Duke University Medical Center have developed a way to deploy sickle-shaped red blood cells to fight cancer tumors by exploiting their ability to adhere to and block the blood vessels surrounding hypoxic tumors. The treatment causes tumor cell death through oxidative stress, resulting in delayed tumor growth.
Researchers have found a novel approach to treating hypoxic solid tumors by using sickle-shaped red blood cells to target and destroy tumor cells and surrounding blood vessels. The sickle cells' unique properties allow them to block tumor blood supply and release toxic residues that promote tumor cell death.
Researchers have demonstrated a feasibility study for activating hemoglobin unaffected by the sickle cell mutation using an animal model. The study showed a five- to 20-fold increase in fetal hemoglobin production, paving the way for further research on correcting disease using gene therapy.
Research found that sickle cell patients experience a significant increase in emergency department visits and hospitalizations as they transition from childhood to adulthood. The study, which analyzed data from over 3,200 patients, showed that emergency room visits tripled between ages 15-24.
Research identifies key challenges in providing adequate care to adult SCD patients, including increased reliance on emergency departments and hospitalizations. The studies suggest that targeted interventions can reduce unnecessary medical utilization and promote long-term disease management, ultimately improving health outcomes for th...
Scientists have gained a deeper understanding of how abnormal red blood cells disrupt circulation in sickle cell disease. The study found that hemoglobin abnormalities play a crucial role in occluding vessels, highlighting potential targets for new treatment strategies.
Researchers at Drexel University identified the physical forces in red blood cells and blood vessels underlying the symptoms of sickle cell disease. They found that rigid sickle cells do not get stuck in narrow capillaries, but instead cause partial obstructions in wider vessels.
In a preliminary clinical trial, half-matched bone marrow transplants successfully eliminated sickle cell disease in 11 of 17 patients. The transplants, which used donated marrow from partially matched donors, also improved blood test results and reduced the need for pain medications.
A new study from the University of Michigan found that parents of newborns with sickle cell anemia are less likely to receive genetic counseling than those whose babies are cystic fibrosis carriers. This disparity may be due to physicians' perceptions of the risks associated with each condition.
A targeted educational approach teaches young patients to remain motionless during MRI scans, making the process safer for children with sickle cell disease. The study found that children who completed a brief preparation program were eight times more likely to undergo successful MRI tests without sedation.
Tim Townes receives $20,000 HudsonAlpha Prize for his groundbreaking work on reprogramming cells to treat sickle cell anemia. His research successfully corrects the DNA mutation associated with the disease, producing healthy red blood cells.
Researchers found that regular exercise reduces oxidative stress in individuals with sickle cell trait, increasing antioxidants and nitric oxide levels. This reduction in oxidative stress may help combat the increased morbidity and mortality associated with SCT.
Researchers have developed a simple blood test that can predict which patients with sickle cell disease are at high risk for painful complications. The device measures blood flow through a microfluidic device, allowing doctors to monitor patients and determine the best course of treatment.
Prevention strategies that included ultrasound screening and chronic blood transfusions for children with sickle cell anemia led to a significant decrease in racial disparities in stroke-related deaths. This change occurred after the Stroke Prevention Trial in Sickle Cell Anemia (STOP) was implemented in 1998.
Researchers evaluated the safety and efficacy of hydroxyurea therapy in pediatric patients with SCD and found that continued use of hydroxyurea was associated with lower rates of pain crises, episodic transfusions, and hospital admissions. The studies also showed high acceptance rates for hydroxyurea among families of children with SCD.
A researcher is conducting a study to determine if variations in genes that play a role in metabolizing opioids can help manage sickle cell pain. The goal is to identify patients who are most likely to experience severe pain and target them for aggressive personalized care.
Researchers at the Salk Institute have developed a new gene editing technique that uses patients' own cells to correct genetic mutations in the HBB gene, which causes sickle cell disease. The method repairs the beta-globin gene without introducing harmful genes into cells and appears to be more efficient than traditional techniques.
A recent study has found that nearly a third of children with sickle cell disease have suffered silent strokes, highlighting the need to identify early signs of anemia and high blood pressure. Researchers believe anemia is the key factor contributing to these risk silent strokes.
A study found that children with sickle cell anemia are at risk for silent cerebral infarcts due to low hemoglobin levels, high systolic blood pressure, and male gender. The risk of silent strokes increases by age six, with over 25% of children suffering a stroke by then.
Blood disorders are a significant public health concern, affecting at least 1 million Americans, with limited understanding of their magnitude. A proposed public health framework aims to address the needs of people with rare blood disorders, including early screening, education, and access to care.
Researchers have discovered a key trigger for producing normal red blood cells that could lead to a new treatment for those with sickle cell disease. Increasing the expression of proteins TR2 and TR4 more than doubled the level of fetal hemoglobin produced in sickle cell mice, reducing organ damage.
Scientists have identified a key player in regulating fetal hemoglobin levels, paving the way for new treatments of sickle cell disease. Silencing a specific protein called BCL11A can reactivate fetal hemoglobin production, effectively reversing the condition in adult mice.
Researchers have corrected sickle cell disease in adult mice by activating the production of fetal hemoglobin, a protein that reduces the tendency of sickle hemoglobin to change red blood cells. This approach builds upon earlier studies and offers a new target for future therapies.
A study by researchers at Children's Hospital Boston and Dana-Farber Cancer Institute finds that deactivating the BCL11A protein can correct sickle cell disease in mice by activating fetal hemoglobin. The findings provide strong evidence that BCL11A could be a powerful treatment target for sickle cell disease and related blood disorders.
Researchers at Wake Forest Baptist Medical Center found no association between sickle cell trait and risk of non-diabetic or diabetic end-stage kidney disease. The study contradicts earlier findings that suggested having one copy of the sickle cell gene increased kidney disease risk.
Researchers found that children with malaria are more susceptible to bacteraemia due to the infection itself, not a natural protection from the sickle cell gene. Malaria prevention strategies may also reduce invasive bacterial infections, with an estimated 50% of cases in endemic areas attributed to Plasmodium falciparum.
Researchers will create the largest library of sickle cell disease-specific iPS cell lines to study the disease's genetic context and develop new therapies. The goal is to understand how specific genes behave in different tissues and clarify the mechanisms by which a gene associated with a disease affects tissue biology.
Research reveals most children with SCD do not feel supported by schools in catching up on absences from class. Schools are often divided on whether others should know a pupil has the condition, fearing it may intensify bullying.
Pomalidomide increases production of fetal hemoglobin, boosting red blood cells in patients with sickle cell disease. Unlike hydroxyurea, pomalidomide preserves bone marrow function without suppressing it.
The BABY HUG trial shows that hydroxycarbamide safely prevents early organ damage and reduces common complications of sickle cell disease in very young children. The study's findings suggest that hydroxycarbamide therapy should be considered for all young children with the disease, regardless of symptoms.